Filter posts

The Washington Post Unfairly Attacks The Orphan Drug Act

The Orphan Drug Act has been a tremendous success and addressed a market failure by …

FDA Commissioner Califf to Industry at #BIO2016: Talk to Patients

Industry should work with patients and their advocates to better understand their experiences, what they’re …

Expanding the Role of Patients in Drug Development

Working alongside scientists, universities, and biotech companies, patients and patient organizations have the ability to …

More Than 90 Patient Organizations Urge Congress to Protect Patients and Innovation

Today, the Epilepsy Foundation and a diverse group of more than 90 advocacy organizations submitted …

BIO Principles on Expanded Access to Investigational, Unapproved Medicines

Seriously ill patients with limited or no alternative therapies, and who are ineligible or unable …

Coalition Offers a Remedy for Stagnated Clinical Trials

Promising new clinical trial data offers fresh hope for the families of Alzheimer’s patients.  A …

The Value of Innovation to Save and Transform Lives

Patients have greater hope for cures to today’s most complex and challenging diseases thanks to …

Mito What???

Mitochondrial Disease: The Most Common Disease You’ve Probably Never Heard of… About 20 years ago, …

BioCentury TV This Week: 340B Drug Discount Program Needs More Oversight

BIO’s Laurel Todd shared concerns that the 340B program has departed significantly from its original …

AIR 340B: New Analysis Shows Most 340B Hospitals Provide Little Charity Care

Today, the Alliance for Integrity and Reform of 340B (AIR 340B) released a new report, …